Alpha Tau Medical Ltd.

NasdaqCM DRTS

Alpha Tau Medical Ltd. Free Cash Flow Yield on December 30, 2024

Alpha Tau Medical Ltd. Free Cash Flow Yield is NA on December 30, 2024, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Alpha Tau Medical Ltd. 52-week high Free Cash Flow Yield is NA on December 30, 2024, which is NA below the current Free Cash Flow Yield.
Alpha Tau Medical Ltd. 52-week low Free Cash Flow Yield is NA on December 30, 2024, which is NA below the current Free Cash Flow Yield.
Alpha Tau Medical Ltd. average Free Cash Flow Yield for the last 52 weeks is NA.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqCM: DRTS

Alpha Tau Medical Ltd.

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street
Employees	121
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends

Past 5 years